---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-083046"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:15:42.317315+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve Amended 2014 Plan adding 4.75M shares; annual meeting results

## Summary
- Stockholders approved Amended 2014 Equity Incentive Plan, increasing authorized shares by 4,750,000.
- Elected Helen Collins, M.D., Thomas Malley, and Carol Schafer as Class II directors until 2028.
- Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2025.
- Advisory vote on executive compensation approved with 63,155,796 for, 1,522,754 against.

## SEC filing metadata
- accession: 0000950170-25-083046
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/0000950170-25-083046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/kura-20250605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-083046
- JSON: https://secwatch.observer/filing/0000950170-25-083046.json
- Plain text: https://secwatch.observer/filing/0000950170-25-083046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.